TLC Announces Topline Results for TLC590 Phase II Trial for Postsurgical Pain Management following Bunionectomy
May 31, 2020 00:09 ET
|
TLC
SOUTH SAN FRANCISCO, CA and TAIPEI, Taiwan, May 31, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target...
TLC Announces Early Completion of Patient Enrollment in TLC590 Phase II Clinical Trial following Bunionectomy
February 12, 2020 04:00 ET
|
TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Feb. 12, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...
TLC Announces Part 1 Analysis of TLC590 Phase II Clinical Trial for Postsurgical Pain Management following Bunionectomy
June 14, 2019 04:45 ET
|
TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, June 14, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and...
TLC Announces Full Enrollment in Part 1 of Phase II Trial of TLC590 for Postsurgical Pain Management following Bunionectomy
April 08, 2019 05:00 ET
|
TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, April 08, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and...
TLC Announces First Patient Dosed in Phase II Trial of TLC590 for Postsurgical Pain Management following Bunionectomy
March 18, 2019 05:00 ET
|
TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, March 18, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and...
TLC Reports Positive Top-Line Results from Phase I/II Clinical Trial of TLC590 for Postsurgical Pain
March 11, 2019 06:27 ET
|
Taiwan Liposome Company, Ltd.
TAIPEI, Taiwan and SOUTH SAN FRANCISCO, Calif., March 11, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and...
TLC Announces Phase I/II Full Enrollment in Hernia Repair Surgery and Phase II Initiation in Bunionectomy of TLC590 for Postsurgical Pain
December 18, 2018 05:30 ET
|
Taiwan Liposome Company, Ltd.
TAIPEI, Taiwan and SOUTH SAN FRANCISCO, Calif., Dec. 18, 2018 (GLOBE NEWSWIRE) -- Taiwan Liposome Company, Ltd. (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated...
TLC Doses First Patients in Phase I/II Trial of TLC590 for Postsurgical Pain Management
August 14, 2018 04:55 ET
|
Taiwan Liposome Company, Ltd.
TAIPEI, Taiwan and SOUTH SAN FRANCISCO, Calif., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Taiwan Liposome Company, Ltd. (4152.TWO; “TLC”), a clinical-stage specialty pharmaceutical company dedicated to the...